FibroGen, Inc(NASDAQ:FGEN) 
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for...
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 7.25
H 8.00
L 6.75
C 7.00
V 1,694,716
10EMA 7.00
20EMA 7.00
60EMA 7.00
120EMA 7.00
250EMA 7.00